aristolochic acid i has been researched along with epoetin alfa in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Angeletti, A; Cantarelli, C; Cravedi, P; D'Agati, VD; Donadei, C; Fiaccadori, E; Guglielmo, C; Hartzell, S; Heeger, PS; Horwitz, JK; La Manna, G; Madsen, JC; Maggiore, U; Xiong, H | 1 |
1 other study(ies) available for aristolochic acid i and epoetin alfa
Article | Year |
---|---|
Erythropoietin inhibits SGK1-dependent TH17 induction and TH17-dependent kidney disease.
Topics: Animals; Aristolochic Acids; Cells, Cultured; Disease Models, Animal; Epoetin Alfa; Erythropoietin; Female; Humans; Immediate-Early Proteins; Interleukin-17; Lupus Nephritis; Male; Mice; Mice, Inbred MRL lpr; Mice, Transgenic; Nephritis, Interstitial; Phosphorylation; Primary Cell Culture; Protein Serine-Threonine Kinases; Receptors, Erythropoietin; Receptors, Interleukin; Severity of Illness Index; T-Lymphocytes, Regulatory; Th17 Cells | 2019 |